PDCD1 and myeloid sarcoma: Targeting PD-1/PD-L1 by direct administration of agonists or indirect upregulated expression may be potential specific treatments for MS, mirroring success of PD-1/PD-L1 reinforcement in the treatment of autoimmunity.